|
Characteristics of long- versus short-surviving patients (Pts): An analysis of the ARIES Observational Cohort Study (OCS) of bevacizumab (BV)-treated pts with metastatic colorectal cancer (mCRC). |
|
|
Consulting or Advisory Role - Roche/Genentech |
Other Relationship - Roche/Genentech |
|
|
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Genentech; Lilly |
Research Funding - Bayer; Eisai; Genentech; Lilly |
Travel, Accommodations, Expenses - Bayer; Eisai; Genentech; Lilly |
|
|
No Relationships to Disclose |
|
|
Honoraria - Celgene; onyx; Sanofi |
Speakers' Bureau - Celgene; Lilly; Sanofi |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Lilly; Regeneron |
Research Funding - NCCN; NCI; Oncolytics |
Expert Testimony - Helsinn Therapeutics |
Other Relationship - Exelixis; Polaris |
|
|
Travel, Accommodations, Expenses - Takeda |
|
|
|
Stock and Other Ownership Interests - Genentech |
Travel, Accommodations, Expenses - Genentech |
|
|
|
Stock and Other Ownership Interests - Genentech |
Travel, Accommodations, Expenses - Genentech |
Other Relationship - Genentech |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
Stock and Other Ownership Interests - Genentech |
|
|
No Relationships to Disclose |
|
|
Honoraria - Genentech/Roche; Lilly/ImClone |
Consulting or Advisory Role - Acceleron Pharma; Amgen; Bayer; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Incyte; Lilly; Novartis; Regeneron; Sanofi; TRACON Pharma |
Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); TRACON Pharma (Inst) |